ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
R-ESHAP consists of: Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes Etoposide, an epipodophyllotoxin topoisomerase inhibitor Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes High-dose Ara-C - cytarabine Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
Dosing regimen Drug Dose Mode Days Rituximab 375 mg/m2 IV infusion Day 0 Etoposide 40 mg/m2 IV infusion over 1 hr Days 1-4 Solu-Medrol - Methylprednisolone 500 mg IV bolus over 15 min Days 1-5 High-dose Ara-C — cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 5 Platinol (cisplatin) 25 mg/m2 IV continuous infusion over 24 hrs Days 1-4
References